In this issue of LRG Science: based on current studies, this article asserts the belief that placebos do not benefit patients with advanced disease.
Dr. Jason Sicklick of Moores Cancer Center at UC San Diego dedicated his new research lab to the memory of GISTer Merak Melikian Hatounian.
A recent study in Cancer Genetics, International initiative for a curated SDHB variant database improving the diagnosis of hereditary paraganglioma and pheochromocytoma, is important for GIST patients who carry a germline SDHB mutation
Two new studies were published in July and August 2021 focusing on SDH-deficient tumor models and how location can affect GIST tumor profiles and drug sensitivity.
Publicado por Colectivo GIST España - Concluimos el mes dedicado a la concienciación del sarcoma & GIST publicando una actualización del tratamiento para los tumores GIST avanzados.
The Life Raft Group celebrated GIST Awareness Day 2021 by holding an virtual, interactive Q&A session for SDH-deficient GIST patients with leading experts in the field.
Become a GEM today! Help us continue our programs and services for GIST patients by giving a monthly recurring donation. Every little bit helps us to further research and support GIST patients and caregivers.
June 28th Awards Ceremony registration: https://livingrare.org/rare-impact-awards/ Dr. Jason Sicklick, Blueprint Medicines Among Honorees Released 2/23/21 by NORD The National Organization for Rare Disorders (NORD®) announced this year’s Rare Impact Award honorees. These outstanding [...]
The 2020 GIST award goes to Dr. Thomas Mühlenberg of the University of Duisburg-Essen The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST), has awarded its science prize for [...]
The annual meeting of CTOS (Connective Tissue Oncology Society) will be held virtually this year due to the global pandemic.